Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balicatib observational safety follow-up extension after studies 2203 and 2203E1
2007-002243-25Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of balicatib in osteoporosis and osteopenia (5 arms), sponsored by Novartis. Primary endpoints: Exploratory safety signal objective 1 and Exploratory safety signal objective 2. Started Jul 2007; status: completed.
02
Drugs
balicatib
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2007-002243-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002243-25.